Analystreport

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is now covered by analysts at Roth Capital. They set a "buy" rating and a $8.00 price target on the stock.

Cyclacel Pharmaceuticals, Inc.  (CYCC) 
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations